AU2014248377B2 - Methods and compositions for treating cancers having acquired resistance to chemotherapeutic and targeted drugs using carboxyamidotriazole orotate - Google Patents

Methods and compositions for treating cancers having acquired resistance to chemotherapeutic and targeted drugs using carboxyamidotriazole orotate Download PDF

Info

Publication number
AU2014248377B2
AU2014248377B2 AU2014248377A AU2014248377A AU2014248377B2 AU 2014248377 B2 AU2014248377 B2 AU 2014248377B2 AU 2014248377 A AU2014248377 A AU 2014248377A AU 2014248377 A AU2014248377 A AU 2014248377A AU 2014248377 B2 AU2014248377 B2 AU 2014248377B2
Authority
AU
Australia
Prior art keywords
cto
acquired resistance
patient
medicament
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014248377A
Other languages
English (en)
Other versions
AU2014248377A1 (en
Inventor
Rashida A. Karmali
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tactical Therapeutics Inc
Original Assignee
Tactical Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tactical Therapeutics Inc filed Critical Tactical Therapeutics Inc
Publication of AU2014248377A1 publication Critical patent/AU2014248377A1/en
Application granted granted Critical
Publication of AU2014248377B2 publication Critical patent/AU2014248377B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2014248377A 2013-04-01 2014-03-28 Methods and compositions for treating cancers having acquired resistance to chemotherapeutic and targeted drugs using carboxyamidotriazole orotate Active AU2014248377B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/986,103 US9089570B2 (en) 2010-09-03 2013-04-01 Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
US13/986,103 2013-04-01
PCT/US2014/032253 WO2014165412A2 (en) 2013-04-01 2014-03-28 Methods and compositions for treating cancers having acquired resistance to chemotherapeutic and targeted drugs using carboxyamidotriazole orotate

Publications (2)

Publication Number Publication Date
AU2014248377A1 AU2014248377A1 (en) 2015-09-03
AU2014248377B2 true AU2014248377B2 (en) 2018-02-01

Family

ID=51621074

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014248377A Active AU2014248377B2 (en) 2013-04-01 2014-03-28 Methods and compositions for treating cancers having acquired resistance to chemotherapeutic and targeted drugs using carboxyamidotriazole orotate

Country Status (10)

Country Link
US (1) US9089570B2 (https=)
EP (1) EP2981169B1 (https=)
JP (1) JP6410795B2 (https=)
KR (2) KR20210019116A (https=)
CN (1) CN105120663B (https=)
AU (1) AU2014248377B2 (https=)
CA (1) CA2902144C (https=)
IL (1) IL241827B (https=)
WO (1) WO2014165412A2 (https=)
ZA (1) ZA201506037B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11186640B2 (en) * 2014-07-31 2021-11-30 The University Of Western Australia Method for the identification of immunotherapy-drug combinations using a network approach
EP3423105B1 (en) 2016-03-02 2021-05-05 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
CN107890467A (zh) * 2017-11-24 2018-04-10 中国医学科学院基础医学研究所 干扰能量代谢的药物在胰腺癌复发中的应用
US20220168276A1 (en) * 2020-08-05 2022-06-02 Tactical Therapeotics Inc. Mehods and Compositions for Treating SARS-CoV-2 Infection using Carboxyamidotriazole Orotate
WO2024208247A1 (zh) * 2023-04-04 2024-10-10 广东银珠医药科技有限公司 羧胺三唑在制备治疗肿瘤骨转移的药物中的用途
WO2024235217A1 (zh) * 2023-05-15 2024-11-21 广东银珠医药科技有限公司 一种抗肺癌联合用药物及其应用
CN119971050A (zh) * 2023-11-10 2025-05-13 广东银珠医药科技有限公司 羧胺三唑与化疗药的组合物及联用治疗实体瘤的用途
CN120817906A (zh) * 2024-04-12 2025-10-21 广东银珠医药科技有限公司 一种三氮唑类化合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2575902C (en) * 1995-07-21 2010-06-08 Tactical Therapeutics Inc Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide
US5728707A (en) 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
US8034823B2 (en) * 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
US7750018B2 (en) * 2006-12-06 2010-07-06 Tactical Therapeutics, Inc Use of carboxiamidotriazole (CAI) orotate in macular degeneration
CN101801983B (zh) * 2007-08-13 2014-01-29 辛塔制药公司 调控hsp90活性的三唑化合物
CN101669941B (zh) * 2008-09-09 2012-11-07 中国医学科学院基础医学研究所 一种联合用药治疗恶性肿瘤的方法以及抗恶性肿瘤的药物
MX2012002730A (es) * 2009-09-04 2012-07-20 Tactical Therapeutics Inc Nuevas composiciones y procesos para preparar formulaciones de 1,2,3-triazoles 5-amino o amino sustituidos y triazol orotato.
US8877785B2 (en) * 2009-09-04 2014-11-04 Tactical Therapeutics Inc Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CORRADO, C et al. "Carboxyamidotriazole-Orotate Inhibits the Growth of Imatinib-Resistant Chronic Myeloid Leukaemia Cells and Modulates Exosomes-Stimulated Angiogenesis". PLoS ONE, 2012, Vol.7(8) e42310 *
KARMALI, R et al. "Antitumor activity of CTO given orally in combination with temozolomide in the SC251 human glioblastoma model." Journal of Clinical Oncology, 2010, Vol. 28, suppl; abstract e13643 *
KARMALI, R et al. "Carboxyamidotriazole Orotate and Cytotoxic Chemotherapy have a Synergistic Effect on Tumor Inhibition in Glioblastoma and Colon Xenograft Mouse Models". Cancer Therapy, 2011, Vol 8: pages 71-81 *
KARMALI, R et al. "Combinatorial treatment with carboxyamidotriazole orotate and temozolomide in sc-implanted human LOX IMVI melanoma xenografts". Journal of Solid Tumors, 2012, Vol. 2(5) pages: 13-28 *

Also Published As

Publication number Publication date
CA2902144C (en) 2021-02-09
EP2981169A2 (en) 2016-02-10
EP2981169A4 (en) 2016-09-14
WO2014165412A3 (en) 2015-01-29
JP2016515619A (ja) 2016-05-30
AU2014248377A1 (en) 2015-09-03
IL241827B (en) 2019-02-28
KR20210019116A (ko) 2021-02-19
KR20160026824A (ko) 2016-03-09
US9089570B2 (en) 2015-07-28
US20140294806A1 (en) 2014-10-02
ZA201506037B (en) 2021-09-29
JP6410795B2 (ja) 2018-10-24
CA2902144A1 (en) 2014-10-09
CN105120663A (zh) 2015-12-02
WO2014165412A2 (en) 2014-10-09
HK1214921A1 (zh) 2016-08-12
EP2981169B1 (en) 2021-05-05
CN105120663B (zh) 2017-08-04

Similar Documents

Publication Publication Date Title
AU2014248377B2 (en) Methods and compositions for treating cancers having acquired resistance to chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
Park et al. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib
Tan et al. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer
JP6784668B2 (ja) 相乗的オーリスタチン組合せ
Dhawan et al. Differential toxicity in patients with and without DNA repair mutations: phase I study of carboplatin and talazoparib in advanced solid tumors
CN113750091B (zh) 用于治疗癌症的方法
AU2012257727B2 (en) Method for EGFR directed combination treatment of cancer
Baik et al. Targeted therapy for brain metastases in EGFR-mutated and ALK-rearranged non-small-cell lung cancer
Kimple et al. Radiosensitization of epidermal growth factor receptor/HER2–positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status
US20210015787A1 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
Mayer et al. A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer
Ghiringhelli et al. Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II study
Figlin et al. NCCN Task Force Report: mTOR inhibition in solid tumors
Wang et al. Molecular treatment of different breast cancers
Canu et al. Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo
Reck et al. Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study
KR20210010524A (ko) 샘낭암종을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조성물
Anzai et al. Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer
Sangha et al. Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial
WO2010132596A1 (en) Use of picoplatin to treat colorectal cancer
US20160367553A1 (en) Methods and Compositions for Treating Cancers having Acquired Resitance to prior Chemotherapeutic and Targeted Drugs Using Carboxyamidotriazole Orotate
Lin et al. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
HK1214921B (en) Methods and compositions for treating cancers having acquired resistance to chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
He et al. Anti-angiogenic therapy for colorectal cancer: on the way to getting better!
Garces et al. Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)